Trastuzumab rezetecan

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody drug conjugate
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody drug conjugate
www.ebi.ac.uk
Drug name
Trastuzumab rezetecan
www.ebi.ac.uk

  • famitinib shr a1811
  • immunoglobulin g1 anti human epidermal growth factor receptor her2 human mus musculus monoclonal shr 1805 γ1 chain complex with human mus musculus monoclonal shr 1805 κ chain dimer thioether with n 6 3 mercapto 2 5 dioxo 1 pyrrolidinyl 1 oxohexyl glycylglycyl l phenylalanyl n 1r 1 cyclopropyl 2 1s 9s 9 ethyl 5 fluoro 2 3 9 10 13 15 hexahydro 9 hydroxy 4 methyl 10 13 dioxo 1h 12h benzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl amino 2 oxoethoxy methyl glycinamide
  • immunoglobulin g1 kappa anti homo sapiens erbb2 epidermal growth factor receptor 2 receptor tyrosine protein kinase erbb 2 egfr2 her2 her 2 p185c erbb2 neu cd340 humanized monoclonal antibody conjugated via a cleavable linker with a camptothecin derivative
  • immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody, conjugated via a cleavable linker with a camptothecin derivative
  • Immunoglobulin G1, anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal SHR-1805 γ1-chain), complex with human-Mus musculus monoclonal SHR-1805 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[(1R)-1-cyclopropyl-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]glycinamide
  • shr a1811
  • Shr a1811
  • SHR- A1811
  • SHR-A1811
  • SHR-A1811 for injection
  • SHR-A1811 for Injection
  • SHR-A1811 Injection
  • SHR-A1811 Subcutaneous Injection
  • trastuzumab rezetecan
  • Trastuzumab rezetecan
  • Trastuzumab Rezetecan
  • Trastuzumab Rezetecan (SHR-A1811)
  • trastuzumab rezetecan [INN]
  • Trastuzumab rezetecan [WHO-DD]
  • Trastuzumab Rezetecan for Injection
  • Trastuzumab Rezetecan for Injection (SHR-A1811)
  • trastuzumab rezetecan inn
  • trastuzumab rezetecan who dd

CAS registry numbers
  • 2647845-11-0
ChEMBL ID
CHEMBL5314712
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 1000BJC8CR

Patents
0
Designations
1
First in class
No
Fast track
No
Breakthrough designation
No
Orphan designation
No
Priority review
No
Orphan exclusivity
No
Accelerated approval
No

Drug name stem
-mab; -mab; -tecan

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0000521
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0001056
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0002158
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0002974
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0003060
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0003219
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0004992
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005036
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005140
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005233
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005494
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005575
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0007254
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0008170
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0008177
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0009831
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0015686
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0018364
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0040679
    Highest recorded phase
    2

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    300 $ 300 ''
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 147-203 $ 147''-203'' $ 223-214' $ 223''-214''' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''

Related records

Trials (111)

In development for (2)